Abstract
We evaluated the efficacy of DAV (DTIC, ACNU and VCR) regimen as adjuvant therapy after surgery in patients with malignant melanoma. We conducted a retrospective comparative study by the presence of DAV, with primary endpoints of relapse-free survival (RFS) and melanoma-specific survival (MSS) with stage II and III melanoma. The Kaplan-Meier method showed that there was no significant difference in RFS and MSS between the two groups. By the Cox proportional hazards model including DAV, sex, age, location, thickness, ulceration, stage and IFN-β as covariates, the presence of DAV had no significant strength of influence on either RFS or MSS. A multicenter, prospective comparative study will be required to continue DAV as a standard adjuvant chemotherapy.[Skin Cancer (Japan) 2009 ; 24 : 229-233]
